Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway  by Morales, Ana I. et al.
see commentary on page 841
Metformin prevents experimental
gentamicin-induced nephropathy
by a mitochondria-dependent pathway
Ana I. Morales1,5, Dominique Detaille1,5, Marta Prieto1, Angel Puente1, Elsa Briones2, Miguel Are´valo3,
Xavier Leverve4, Jose´ M. Lo´pez-Novoa1 and Mohamad-Yehia El-Mir1
1Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain; 2Department of Pharmacy and
Pharmacological Technology, University of Salamanca, Salamanca, Spain; 3Department of Anatomy and Human Histology, University
of Salamanca, Salamanca, Spain and 4INSERM U884, Fundamental and Applied Bioenergetics, University Joseph Fourier of Grenoble,
France
The antidiabetic drug metformin can diminish apoptosis
induced by oxidative stress in endothelial cells and prevent
vascular dysfunction even in nondiabetic patients. Here we
tested whether it has a beneficial effect in a rat model of
gentamicin toxicity. Mitochondrial analysis, respiration
intensity, levels of reactive oxygen species, permeability
transition, and cytochrome c release were assessed 3 and
6 days after gentamicin administration. Metformin treatment
fully blocked gentamicin-mediated acute renal failure. This
was accompanied by a lower activity of N-acetyl-b-D-
glucosaminidase, together with a decrease of lipid
peroxidation and increase of antioxidant systems. Metformin
also protected the kidney from histological damage 6 days
after gentamicin administration. These in vivo markers of
kidney dysfunction and their correction by metformin were
complemented by in vitro studies of mitochondrial function.
We found that gentamicin treatment depleted respiratory
components (cytochrome c, NADH), probably due to the
opening of mitochondrial transition pores. These injuries,
partly mediated by a rise in reactive oxygen species from the
electron transfer chain, were significantly decreased by
metformin. Thus, our study suggests that pleiotropic effects
of metformin can lessen gentamicin nephrotoxicity and
improve mitochondrial homeostasis.
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The major clinical problem in the use of gentamicin, an
aminoglycoside antibiotic extensively used in the treatment
of Gram-negative bacterial infection,1 is its nephrotoxicity
even at the lowest therapeutic doses.2 Indeed, in addition to
tubular toxicity, a part of gentamicin-induced renal damage
is based on its glomerular effects, especially those altering the
function of mesangial cells.3–5
Conversely, mitochondria are increasingly believed to have
a crucial role in a broad spectrum of renal diseases.6,7 As the
kidney is the main excretory route, through the process of
filtration and secretion, for various drugs, some of which may
be mitochondrial toxins, mitochondrial dysfunction could
have a major role in nephrotoxicity. Previous experiments in
a rat model reported that gentamicin inhibited oxidative
phosphorylation and reduced ATP levels in renal tubular
cells.8 Evidence also pointed to mitochondrial pathway-
dependent oxidative stress in renovascular defects.9,10 In fact,
numerous in vivo and in vitro studies showed that reactive
oxygen species (ROS) were often involved in the onset and
progression of these injuries.11,12 Similarly, ROS-induced cell
death processes were proposed to have a relevant role in
gentamicin-mediated acute renal failure, characterized by
necrosis of proximal tubular cells13,14 and simultaneous
occurrence of glomerular cell proliferation and apoptosis.15,16
Interestingly enough, gentamicin enhanced ROS formation
in isolated cortical mitochondria.17
We previously reported that treatment with resveratrol, a
natural antioxidant, modulated the toxic effects of gentami-
cin by preventing increase in oxidative stress.18 Similar
protective effects on renal function in response to gentamicin
injection were found with other ROS scavengers.19–21
However, the exact biochemical mechanisms involved in
nephroprotection, as well the specific contribution of
mitochondria in this event, were barely examined in most
of these studies. On the contrary, data revealing the
preventive actions of metformin, a reference medication for
prime treatment of type-2 diabetes and its long-term
complications,22 have accumulated over the past few years.
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2010 International Society of Nephrology
Received 3 March 2009; revised 12 November 2009; accepted 8
December 2009; published online 17 February 2010
Correspondence: Mohamad-Yehia El-Mir, Department of Physiology and
Pharmacology, University of Salamanca, Campus Miguel de Unamuno,
Edificio Departamental S-12, Salamanca 37007, Spain. E-mail: elmir@usal.es
5These authors contributed equally to this work.
Kidney International (2010) 77, 861–869 861
Recent investigations strongly showed that this antidiabetic
agent prevented oxidative stress-induced death in several cell
types,23,24 including human endothelial cells,25 through a
mechanism dependent on the mitochondrial permeability
transition pore (PTP) opening. Importantly, a randomized
comparative trial showed that, for an equivalent effect on
glycemic control after years of treatment, metformin
was largely superior to other therapeutic measures for
reducing vessel diseases and all-cause-related mortality.26
Therefore, the aim of this study was to examine the potential
properties of metformin protecting the kidney from a
nephrotoxicant insult, as well to investigate the main
underlying mechanisms.
RESULTS
Gentamicin-induced renal dysfunction and associated
oxidative stress are both reversed by metformin
Gentamicin exposure led to acute renal failure, as evidenced
by decreased creatinine clearance and increased excretion of
N-acetyl-b-D-glucosaminidase (Table 1). Treated animals also
had a lower glomerular filtration rate (Figure 1a), reduced
renal plasma flow (RPF) and blood flow (RBF) (Figure 1b
and c), as well as higher renal vascular resistance (Figure 1d)
than control rats. Metformin fully mitigated this nephrotoxic
profile as rats receiving both metformin and gentamicin
showed higher glomerular filtration rate, RPF, and RBF
than gentamicin-treated rats, the end values even reaching
or rising above those in the control group (Figure 1).
Expectedly, lipid peroxidation substantially increased with
gentamicin as compared with that in the control group
(Figure 2a), whereas plasma total antioxidant status (TAS)
simultaneously diminished (Figure 2b). Importantly, metfor-
min, when administered before and together with gentami-
cin, not only normalized lipid peroxidation but also
increased TAS (Figure 2).
Histological changes due to gentamicin toxicity are
prevented by metformin
Light-microscopic examination of kidneys from control and
metformin-treated rats showed no structural alterations in
renal tissues (Figure 3a and c). Massive and diffuse cell
necrosis was observed in the proximal tubules of kidneys
from rats injected with gentamicin. In addition, the tubular
lumen was frequently filled with hyaline casts or hetero-
geneous cellular debris (Figure 3b). In contrast, in rats treated
with gentamicin and metformin, most of the proximal
tubules showed completely viable cells, and manifest necrosis
was observed in less than 10% of cells, although most
Table 1 | Urinary flow, NAG activity, proteinuria, and creatinine clearance in control rats, rats that received a daily
intraperitoneal injection of gentamicin, rats that received metformin-supplemented drinking water, and rats that received
metformin plus gentamicin (n=4, performed in duplicate)
Control Gentamicin Metformin Metformin+gentamicin
Urinary flow (ml day1) 12.5±4.4 7.6±1.5 18.7±10.9 59.8±19.4w,y
NAG activity (AU day1) 0.94±0.17 18.2±4.5w 0.96±0.1 1.6±0.3y
Proteinuria (mg day1) 20.7±5.8 39.9±7.6w 26.3±6.9 15.6±7.9y
Creatinine clearance (ml min1) 1.25±0.015 0.096±0.04w 1.4±0.03 1.3±0.2y
Abbreviation: NAG, N-acetyl-b-D-glucosaminidase.
wPo0.05 versus control; yPo0.05 versus gentamicin.
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Figure 1 | Effect of metformin on gentamicin-induced renal dysfunction in rats. (a) Glomerular filtration rate (GFR), (b) renal blood flow
(RBF), (c) renal plasma flow (RPF), and (d) renal vascular resistance (RVR) were determined in all experimental groups mentioned in Table 1
(n¼ 4). #Po0.05 versus control; *Po0.05 versus gentamicin; zPo0.05 versus metformin.
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proximal tubular cells showed signs of initial cellular
degeneration (Figure 3d).
Paradoxically, such a protection afforded by metformin
against anatomical and functional signs of gentamicin-
induced nephrotoxicity was not accompanied by a reduction,
but rather by an apparent increase in the renal accumulation
of aminoglycoside. Indeed, metformin-treated rats incorpo-
rated two times more gentamicin in their renal cortices than
did rats treated with only gentamicin (1235±192 versus
666±88 mg/g tissue, Po0.05), whereas low amounts of
gentamicin present in the medulla did not significantly vary
between both animal groups (103±13 versus 136±34 mg/g
tissue).
Role of mitochondria in the mechanism of gentamicin-
induced kidney damage, as well as in the protective response
initiated by metformin: key implication of PTP
We propose that a profound mitochondrial dysfunction is at
the origin of gentamicin-caused pathogenesis, leading
ultimately to necrotic degradation of kidney cells. To test
this theory, we addressed the questions of whether PTP
opening and cytochrome c release were involved in
gentamicin toxicity, and how metformin modulated
these events in vivo. This experimental set was mainly
conducted using rats receiving only three doses of gentamicin
to assess the early occurrence of mitochondrial changes.
Similar to that observed in the liver,27 kidney mitochondria
that were energized with glutamate–malate or succinate
absorbed and retained Ca2þ until the final increase in
fluorescence (Figure 4a), indicative of mitochondrial perme-
ability transition induced by calcium overload, and were
also sensitive to cyclosporine-A (CsA), the reference
PTP inhibitor. Metformin increased the Ca2þ amount
required for PTP opening, irrespective of the nature
of respiratory substrates. Importantly, addition of Ca2þ
to mitochondria from rats treated with either three or six
doses of gentamicin, stimulated a release of accumulated
Ca2þ under all conditions, a phenomenon that was hindered
by metformin and CsA (Figure 4b). We next studied
cytochrome c compartmentalization during gentamicin
treatment. For this purpose, the cytosolic and mitochondrial
fractions were isolated from the renal cortex (Figure 5). After
three doses of gentamicin, cytochrome c release into the
cytosol was obvious. Nevertheless, the released part was
o25% of the total cytochrome c and, hence, mitochondrial
cytochrome c did not show a clear decrease. Metformin
ameliorated this cytochrome c delocalization, indicating that
PTP inhibition by metformin provides a potential means of
reducing the nephrotoxicity of gentamicin.
Gentamicin-mediated defects in mitochondrial bioenergetics
are reversed by metformin
Table 2 summarizes all mitochondrial respiration data from
groups receiving gentamicin for 3 or 6 days, either alone or
with metformin, before administration to rats for 1 week.
Compared with control values, gentamicin treatment resulted
in alterations in respiratory chain function independent of
the respiratory fuels used, after as few as three doses of this
nephrotoxicant. Gentamicin mildly reduced the oxygen
consumption rates (Jo2) under the phosphorylating condi-
tion, that is, in the presence of ADP (state-3), and in the
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Figure 2 | Effect of metformin on the oxidative stress in vivo
related to gentamicin-induced nephrotoxicity in rats. (a) Lipid
peroxidation, as estimated by production of thiobarbituric acid-
reactive substances (TBARS) in kidney homogenates and (b) total
antioxidant systems (TAS) of the plasma were accordingly
assessed in the four groups of rats studied. #Po0.05 versus
control; *Po0.05 versus gentamicin.
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Figure 3 | Light micrographs of sections from kidneys stained
with hematoxylin–eosin. (a, c) Normal histology of kidney tissue
in control and metformin-treated rats. (b) Massive necrosis in
proximal tubules (asterisk) with hyaline cast (arrow) is observed in
animals treated with gentamicin (150 mg/kg body weight per day)
for 1 week. (d) Sections from gentamicin—metformin-treated rats
reveal almost complete prevention of histopathological
alterations by the biguanide drug. Bar¼ 50 mm.
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uncoupling state, after DNP addition. Jo2 with TMPD-
ascorbate, used to assess the maximal activity of cytochrome
oxidase, was not altered by gentamicin. After six doses of this
antibiotic, all respiratory values were significantly different
from that of the control; respiration rate in state 4, that is, in
the presence of ATP synthase inhibitor oligomycin, was also
below normal, resulting in no significant change in the
respiratory control index or RCR (state-3/state-4). Metfor-
min, when administrated before gentamicin, prevented this
progressive mitochondrial dysfunction almost completely
(Table 2).
The fact that metformin weakly reduced glutamate/malate-
dependent respiration may be consistent with a physiological
inhibitory effect on the functionally isolated complex-I, which
we previously reported in a quite different setting.28 Here,
complex-I activity from the control mitochondria was
significantly reduced by metformin, and this inhibition was
even preserved in gentamicin-treated rats. On the contrary, the
fact that gentamicin itself drastically lowered complex-I activity
after 6 days of treatment, would be linked more to molecular
alterations (proteolysis, conformational change) in this huge
complex, rather than to a generalized damage of mitochondria,
as citrate synthase activity, an usual indicator of the respiratory
chain content in tissues, was only poorly attenuated (Table 3).
Decline of gentamicin-induced mitochondrial oxidative stress
by metformin
There is a trend toward considering that alterations in the
respiratory chain are responsible for the formation of
excessive amounts of ROS, thereby contributing to cell
damage.29,30 Although hydrogen peroxide (H2O2) levels were
barely affected by gentamicin, when glutamate–malate or
succinate was individually used without inhibitors (Figure 6c
and d), a decrease in NADH fluorescence was found in both
situations (Figure 6a and b). As the main NADH-oxidizing
pathway was blocked by gentamicin (Table 3), an escape of
NADH from mitochondria would therefore be envisaged,
possibly through the open PTP. A gentamicin-related
increase in ROS was especially sizeable in mitochondria res-
piring on both glutamate–malate and succinate (Figure 6e).
Remarkably, metformin prevented the mitochondrion-driven
oxidative stress by lowering or normalizing ROS production
along the respiratory chain (Figure 6c–e). Moreover,
gentamicin-induced depletion of mitochondrial NADH was
highly recovered with metformin treatment under either
glutamate–malate or succinate conditions (Figure 6a and b).
DISCUSSION
Although gentamicin continues to be an irreplaceable
treatment against life-threatening infections, its use remains
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Figure 4 |Calcium retention capacity of kidney mitochondria
isolated from control or gentamicin-treated rats (3 and
6 days), and subjected or not to metformin treatment.
(a) Typical traces obtained after suspension of renal mitochondria
in an incubation medium with respiratory substrates and calcium
green. Where indicated, pulses of 25 mM Ca2þ were added every
minute. CsA, the common inhibitor of the PTP, was directly added
to mitochondria isolated from control rats, treated or not with
gentamicin. (b) Quantitative analysis of the calcium retention
capacity for each experimental set with glutamate–malate
(GM,&), succinate (S,’), glutamate–malateþ succinate (GMS, )
as energizing substrates. #Po0.05 versus control; *Po0.05 versus
gentamicin. No significant difference was found between the two
groups of rats treated for different durations with gentamicin
alone. PTP, permeability transition pore.
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Figure 5 |Cytochrome c release during gentamicin
nephrotoxicity and prevention by metformin. After 3 days of
gentamicin treatment in the absence or presence of metformin,
cortical tissues were freshly collected to isolate the cytosolic and
mitochondrial fractions for cytochrome c immunoblotting. Total
protein concentration is 50 mg per lane in all samples. Cytochrome
c release depicts changes in mitochondrial membrane
permeability. #Po0.05 versus control; *Po0.05 versus gentamicin.
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seriously limited by its nephrotoxicity. Although various
studies reported on the benefits of several agents in
gentamicin-induced renal poisoning,31 the basis of nephro-
protection remains elusive. To the best of our knowledge, this
report is the first to show that metformin, a drug widely used
in the treatment of diabetes, prevents functional, histological,
and biochemical kidney injuries in the setting of gentamicin
insult. Of utmost importance, all these impressive effects,
seen at a metformin dosage corresponding to the clinically
evidenced therapeutic range,32 partly proceed from a
normalization of in vivo oxidative stress and restoration of
mitochondrial functional integrity.
Our findings corroborate those of earlier studies demon-
strating that an enhanced endogenous oxidative stress has a
major role in the severity of gentamicin-induced acute renal
failure.3,17 Although having no effect alone, metformin
blunted alterations in the hemodynamics induced by the
daily injection of a nephrotoxic dose of gentamicin. In
addition, RPF, RBF, and urinary flow even increased
significantly in metformin plus gentamicin-treated rats as
compared with that under baseline conditions. Although
these remarkable outcomes cannot be readily explained, one
may conceive that such a protection afforded by metformin
could be mediated, at least in part, by the in vivo antioxidant
features of this antidiabetic agent recently found,33,34 as well
by its ability to prevent gentamicin-induced lipid peroxida-
tion and to enhance antioxidant defenses in the control and
treated animals (this study). One of the early sensitive
markers of tubular injury after exposure to aminoglycosides
is increased excretion of lysosomal enzymes. Our data
showing that metformin considerably prevented the increase
of gentamicin-induced urinary N-acetyl-b-D-glucosamini-
dase excretion, suggest evident protection against structural
and functional tubular alterations. Strikingly, metformin-
reduced gentamicin toxicity occurs in spite of larger intra-
renal amounts of toxicant. This paradoxical result of high
cortical concentrations of gentamicin with preservation of
renal function was similarly reported by others using rats
treated with a combination of gentamicin and polyaspartic
acid.35 As a cationic drug, metformin is known to be
transported across the kidney through organic cation
transporter-2.36 In the case of gentamicin, the endocytotic
receptor megalin has been reported to be responsible for its
tubular accumulation, which is directly related to its
toxicity.37 The fact that metformin did not diminish
gentamicin accumulation reflects a lack of interaction
between both ways of transport, and suggests that protection
conferred by biguanide occurs from within renal cells.
Table 2 | Oxygen consumption rates (nmol O2/min/mg protein) in kidney mitochondria isolated from control rats or rats
treated with gentamicin for 3 or 6 days, and subject or not to treatment with metformin (n=4–6)
Control
Gentamicin
(3 days)
Gentamicin
(6 days) Metformin
Metformin+
Genta (3 days)
Metformin+
Genta (6 days)
Glutamate/malate
(GM) State-4 17.6±0.4 20.1±1.3 10.2±1.1w 15.8±1.3w 24.9±2.6 15.1±0.9w,y
State-3 148.9±7.2 128.9±9.2w 80.6±2.1w 119.8±6.9w 155.5±3.3y 126.3±8.1y
DNP 150.3±11 103.4±7.1w 76.1±2.2w 129.5±14.4 148.9±15.7y 111.8±7.2w,y
RCR 8.2±0.2 6.4±0.09 7.8±0.4 8.1±0.1 7.1±0.4 8.2±0.3
Succinate+
rotenone State-4 48.4±2.7 52.2±6.1 28.1±1.5w 44.6±3.3 52.6±14.1 40.9±2.3y
State-3 285.9±8.7 235.7±9.2w 125.6±18.2w 286.6±6.7 294.8±20.5y 206.1±12.7w,y
DNP 290.9±16.8 255.8±16.7w 150.9±18.5w 300±18.2 297.3±17.5y 252.8±21.4y
RCR 6.4±0.1 4.7±0.4 5.1±0.2w 6.6±0.3 6.1±0.35 5.8±0.1
TMPD-ascorbate 514.8±42.7 492.5±25.3 330.6±48.6w 503.9±27.1 502.8±19.3 484.5±61.9y
GM+succinate State-4 40.8±2.2 43.7±3.6 24.6±2w 40.1±4 58.7±3.2 39.2±1.4y
State-3 302.7±9.8 231.3±27.3w 145.1±5.3w 314.4±7.7 327.1±17.8y 258.4±24.3y
DNP 296.4±10 210±23 132.7±11.4w 312.1±13.9 318.2±25y 243.5±16.3y
RCR 7.1±0.1 5.05±0.34 6.75±0.3 7.3±0.4 5.8±0.2 6.85±0.2
Abbreviations: DNP, dinitrophenol-uncoupled respiration; RCR, respiratory control ratio; State-3, ADP-stimulated respiration; State-4, basal respiration.
wPo0.05 versus control; yPo0.05 versus gentamicin (3 or 6 days accordingly).
Table 3 |Measurement of functionally isolated respiratory chain complex-I and matrix CS activities in kidney mitochondria
isolated from control or gentamicin-treated rats, and subject or not to treatment with metformin (n=6)
Control Gentamicin Metformin Metformin+gentamicin
CS activity (nmol CoA/min/mg protein) 303.1±6.6 275.2±6.8 302.9±6.7 294.1±6.2
Rotenone-sensitive activity of complex-I (nmol NADH/min/mg protein) 91.7±2.8 38±4.1w 77.6±2.4w 71.7±8.8y
Complex-I/CS (nmol NADH/unit of CS) 0.31±0.01 0.13±0.02w 0.27±0.01w 0.25±0.02y
Abbreviation: CS, citrate synthase.
wPo0.05 versus control; yPo0.05 versus gentamicin.
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Another potentially important finding of this study is that
gentamicin induces drastic mitochondrial changes that
largely precede overt cell necrosis and acute renal failure.
After three doses of gentamicin, mitochondrial damage
included PTP opening and leakage of cytochrome c into
the cytosol, whereas no evident differences in the histology of
treated rats as compared with that in the controls were found,
except for cytoplasmic vacuolization in most of the proximal
tubules (data not shown). It is noteworthy that these initial
mitochondrial abnormalities were improved by metformin. A
progressive deterioration in mitochondrial function and
cellular integrity was observed with increasing gentamicin
dosage. After six doses, PTP opening was higher than that
with three doses and, expectedly, light microscopic examina-
tion revealed serious lesions and necrosis in a large number
of proximal tubular cells. Thus, necroses and shedding of
dead cells into the urine would account for the sharp decline
in cortical gentamicin concentrations. As the harmful effect
of ROS on tissues is widely appreciated, we provide enough
evidence that these cytotoxic effects for gentamicin are partly
associated with mitochondrial oxidative stress. Despite the
presence of non-physiological substrate concentrations,
specific conditions of dual-electron entry at both respiratory
chain site-1 (glutamate/malate) and site-2 (succinate), as it is
most likely the case in living cells, led to higher H2O2
contents after gentamicin treatment, indicating major
derangements along all electron transfer chain segments
and excess generation of ROS. This result correlates with the
reported depletion in plasma antioxidant capacity. Among
the various effects of ROS on cell metabolism, they are
recognized to induce pore opening in either in vitro or in vivo
settings.38 The fact that gentamicin successively triggered
PTP opening, cytochrome c release, and cell necrosis, whereas
metformin prevented almost all these events, strongly argues
that cytotoxicity of gentamicin-mediated stress is likely
related to lowered mitochondrial permeability.
It should be stressed that, in the experimental group
receiving six doses of gentamicin, the resting, ADP-
dependent, and uncoupled respirations all substantially
reduced below control values, yet RCR was marginally
altered. Importantly, gentamicin lowered the respiratory flux
to cytochrome c oxidase, whereas citrate synthase activity did
not vary. Thus, no indication of oxidative phosphorylation
uncoupling by gentamicin was found in this study, contrary
to what others have shown in this field.8 Blockade of
respiration should therefore be explained by a loss of key
mitochondrial components, including cytochrome c, which
we already evidenced above, and also probably NADH. Our
data showing the destructive effect of gentamicin on
complex-I activity, together with the collapse of NADH
autofluorescence irrespective of the substrates used, indirectly
suggest that part of NADH has left the mitochondrial matrix.
Similarly, this process could be attributed to PTP opening.
Indeed, we recently showed that permanent mitochondrial
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Figure 6 |NADH fluorescence and ROS formation in kidney mitochondria incubated with glutamate–malate and/or succinate. Once
mitochondria were isolated from control, gentamicin-, metformin-, and metforminþgentamicin-treated rats, NADH was followed up by
determining its spontaneous autofluorescence; one typical experiment is presented (a, b). Conversely, H2O2 production was assessed by
amplex red/horseradish peroxidase for all the experimental groups (n¼ 6) (c–e). Where indicated, substrates and/or inhibitors were
sequentially added; each reaction was thus started with either glutamate–malate (a, c), succinate (b, d), or both substrates (e). Thereafter,
1 mM rotenone (for both mitochondrial parameters) and 0.125 mM antimycin-A (for ROS measurement only) were added. #Po0.05 versus
control; *Po0.05 versus gentamicin; zPo0.05 versus metformin. ROS, reactive oxygen species.
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pore opening in intact cells inhibited NADH-consuming
processes and allowed the export of NADH outside the
mitochondria.39 It is noteworthy that the unique feature of
metformin, namely a regulatory effect on reverse electron
flux-related ROS formation through mild inhibition of
complex-I that has been depicted using mitochondria
isolated from livers perfused ex vivo with the biguanide,40
was kept in the kidney under gentamicin insult. Indeed,
metformin suppressed this specific ROS production in both
control and gentamicin-treated rats when mitochondria
respired on succinate. This response was also accompanied
by complete recovery of NADH autofluorescence levels.
Finally, even though a weak inhibitory effect of metformin on
complex-I was recorded in either case, we can assume that
these repeated inhibitions and their advantages in terms of
cell survival throughout the treatment have likely had a
preconditioning role in gentamicin toxicity.
Apart from complex-I, it is widely thought that AMP-
activated protein kinase (AMPK), the energy sensor in cell
metabolism, is another crucial target for metformin.41
However, the true underlying mechanisms remain elusive,
even contradictory, and there is actually no simple explana-
tion for the differences between data from a lot of published
studies. Furthermore, there are few relevant results in the
recent literature about the specific action of metformin on
AMPK in the kidney. No significant effect on AMPK
phosphorylation was found in this study with metformin
alone (data not shown). This result is possibly related to the
fact that our conditions are far from protocols using renal
cells incubated with AMPK activators for a short time.42
Further in vivo studies intended to clarify the exact role of
AMPK in mitochondrial metabolism at the kidney level are
thus mandatory.
As both PTP dysregulation and mitochondrial oxidative stress
underlie, at least partly, the toxicity of gentamicin, diverse
strategies to maintain the integrity of these organelles and cellular
viability could be of therapeutic relevance. To a certain extent, the
immunosuppressor CsA that delayed gentamicin-induced pore
opening would be a putative candidate, but, due to wide-ranging
cellular actions that entail side effects and nephrotoxicity,43 its
clinical use is still limited. For its part, metformin might be
envisaged as a prospective alternative, even better than other
antioxidants,44 to hamper gentamicin nephrotoxicity by virtue of
net prevention, which seems to depend on the interrelationship
between complementary processes. In this regard, it is worth
keeping in mind that metformin is eliminated unchanged
through the kidney by glomerular filtration and tubular
secretion.45 This can promote its potential accumulation in the
condition of renal impairment and lead to the rare but most
undesirable metformin complication, namely, lactic acidosis.46
However, a recent study underlined that mild acute renal injury
enhanced metformin amounts in the diabetic rat cortex, without
further worsening renal function or increasing plasma lactate
levels.47 Although metformin is undoubtedly contraindicated in
situations of renal insufficiency, our data along with this latter
report now conduce to reconsider more carefully the limitations
previously defined about the therapeutic applications of this
longstanding medication.48
In conclusion, our results suggest that metformin treat-
ment protects the kidney from gentamicin-induced toxicity,
and that this protection is based, at least in part, on the
correction of gentamicin-induced mitochondrial alterations.
MATERIALS AND METHODS
Animals
Male rats were placed individually into metabolic cages in a
temperature-, humidity-, and light-controlled animal house. They
were divided into six experimental groups: a control group, a
metformin group that received the antidiabetic drug dissolved in
drinking water (100 mg/kg/day) for 13 days, two gentamicin groups
that received a daily intraperitoneal injection of gentamicin
(150 mg/kg), for 3 and 6 days each, and two metformin plus
gentamicin groups that received metformin before and together
with gentamicin for 10–13 days. Rats were treated in accordance
with the protocols of the following institutions: Conseil de l’Europe
(published in the Official Daily N. L358/1-358/6, 18th December
1986) and Spanish Govern-ment (published in Boletı´n Oficial del
Estado N. 67, pp. 8509–8512, 18th March 1988, and Boletı´n Oficial
del Estado N. 256, pp. 31349–31362, 28th October 1990).
Clearance studies
On day 5 after the start of treatment in all concerned experimental
groups, urine samples were collected to assess (i) urinary flow,
(ii) proteinuria using the Bradford method, (iii) creatinine clearance
by the Jaffe´ kinetic reaction, and (iv) the activity of N-acetyl-b-D-
glucosaminidase by a photometric procedure from Roche (Roche
Applied Science, Indianapolis, IN, USA). At the end of the
treatment, the animals were anesthetized with sodium pentobarbital
(40 mg/kg) and placed on a heated board. A tracheotomy was then
performed to facilitate breathing throughout the experiment. Rats
were surgically prepared for clearance studies, while continuously
recording their mean arterial pressure. Urine was collected using a
bladder catheter into vials containing 0.5 ml water-stabilized mineral
oil. An isotonic infusion containing [3H]inulin and [14C]amino-
hippuric acid was started at 3 ml/h using a venous catheter to allow
clearance determinations. After equilibration, three urine samples
were collected at 30 min intervals, with blood sampling at the
beginning and the end of each clearance period. Packed cell volume
was determined by the microcapillary method. [3H] and [14C] rates
were measured of blood and urine samples using a two-channel
liquid scintillation counter (Wallac 1409 DSA, Turku, Finland).
Inulin and [14C]aminohippuric acid clearances were calculated to
measure glomerular filtration rate and RPF, respectively. RBF was
calculated from RPF and packed cell volume. Renal vascular
resistance was calculated from RBF and mean arterial pressure.
Measurement of in vivo oxidative stress
Lipid peroxidation was estimated from a tissue homogenate by
measuring thiobarbituric acid-reactive substances as described pre-
viously.49 Blood samples were collected at day 5 of treatment for analysis
of TAS using a commercial kit (Randox Laboratories LTD, UK).
Light microscopy imaging
Rats used for 24 h urine collections were anesthetized and the
abdomen was opened by means of a midline incision. A perfusion
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catheter was inserted into the abdominal aorta and a renal perfusion
with cold isotonic saline was performed to wash out the blood.
Kidney pieces were trimmed sagitally, fixed by immersion in 4%
buffered formalin for 24 h, embedded in paraffin, sectioned (3 mm
thick), then counterstained with hematoxylin–eosin.
Determination of gentamicin concentrations
The gentamicin concentration in kidney samples was analyzed by
HPLC on the basis of a derivatization with O-phthaldialdehyde and by
fluorescence detection.50 Samples of 20ml were injected into the
chromatograph, and elution was achieved at a flow rate of 1.5 ml/min.
Mitochondrial respiratory chain functioning
Mitochondria, isolated by differential centrifugation from kidneys of
fasted rats as earlier described,51 were used to measure bioenergetic
parameters. After renal mitochondria were suspended in incubation
medium supplemented with glutamate (5 mM)/malate (2.5 mM) or
with succinate (5 mM) in the presence of rotenone as energizing
substrates, Jo2 was recorded at 301C in a constantly stirred oxygraph
vessel after successive additions of 1 mM ADP (state 3), 0.75 mg ml1
oligomycin (state 4), 75 mM DNP (uncoupling), and TMPD–ascor-
bate (1:5 mM). In addition, respiratory chain complex I and matrix
citrate synthase activities were determined spectrophotometrically
using protocols that we previously described.24
H2O2 and NADH autofluorescence levels
Mitochondrial H2O2 generation was measured by monitoring
H2O2-induced fluorescence of probe amplex red (excitation:
560 nm; emission: 583 nm) under the catalysis of horseradish
peroxidase.40 ROS production was stimulated in the presence of
respiratory substrates (the same as that used for Jo2 measurements),
then 1.25mM rotenone and 2mM antimycin-A were sequentially added
to determine the maximun rate of H2O2 production of complexes-I
and Iþ III of the electron transfer chain, respectively. Mitochondrial
NADH levels were monitored by recording its relative fluorescence
intensity (excitation: 340 nm; emission: 460 nm).
Calcium retention capacity and cytochrome c release
The sensitivity of the mitochondrial PTP was evaluated fluorime-
trically by measuring the calcium retention capacity of mitochon-
dria incubated in a suited buffer supplemented with 0.25 mM calcium
green (excitation: 506 nm; emission: 532 nm). The respiratory
substrates were the same as before, and pulses of 25 mM Ca2þ were
added every minute until pore opening. The specificity of this assay
was assessed by adding 1 mM CsA, the standard inhibitor of PTP.
After 3 days of gentamicin treatment, in the absence or presence of
metformin, kidneys were perfused with saline solution, then renal
cortical tissues were freshly collected, homogenized, and fractionated
by differential centrifugation in a cold mitochondrial extraction buffer
as described elsewhere.52 The resulting cytosolic and mitochondrial
fractions were collected, protein contents were quantified, and 50mg
was next fractionated by SDS-polyacrylamide gel electrophoresis,
transferred onto a polyvinylidene difluoride membrane, and probed
with a mouse-purified antibody to cytochrome c (1:1000; BD
Pharmingen, San Jose, CA, USA). Protein expression was quantified
by densitometry using the Scion Image software.
Statistical analysis
All data are represented as mean±s.e.m. Comparisons were made
either by analysis of variance followed by Scheffe’s test for repeated
measurements, or by an appropriate Student’s t-test for a non-
matched series. Po0.05 was taken to indicate statistical significance.
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